c-Met/HGFR
c-Met (hepatocyte growth factor receptor, HGFR) is a protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. c-Met is a membrane receptor that is essential for embryonic development and wound healing. Hepatocyte growth factor (HGF) is the only known ligand of the c-Met receptor. c-Met is normally expressed by cells of epithelial origin, while expression of HGF is restricted to cells of mesenchymalorigin. Upon HGF stimulation, c-Met induces several biological responses that collectively give rise to a program known as invasive growth.
All Product Categories
-
c-Met/HGFR Inhibitors
(236)
View all products
-
c-Met/HGFR Agonist
(1)
View all products
-
c-Met/HGFR Activators
(3)
View all products
-
c-Met/HGFR Modulators
(2)
View all products
-
c-Met/HGFR Degraders
(11)
View all products
-
c-Met/HGFR Ligands
(4)
View all products
-
c-Met/HGFR Proteins
(48)
View all products
-
c-Met/HGFR Related Products (280)
Related Products (280)
-
Recombinant Proteins (48)
-
Antibodies (7)
-
Golvatinib (Standard)
0 ImagesCat. No.: HY-13068RCAS No.: 928037-13-2Synonyms: E-7050 (Standard)Golvatinib (Standard) is the analytical standard of Golvatinib. This product is intended for research and analytical applications. Golvatinib (E-7050) is a potent dual inhibitor of both c-Met and VEGFR2 kinases with IC50s of 14 and 16 nM, respectively.
-
Elzovantinib (Standard)
0 ImagesCat. No.: HY-111787RCAS No.: 2271119-26-5Synonyms: TPX-0022 (Standard); CSF1R-IN-2 (Standard)Elzovantinib (Standard) is the analytical standard of Elzovantinib (HY-111787). This product is intended for research and analytical applications. Elzovantinib (TPX-0022) is an oral-active inhibitor of SRC, MET and c-FMS, with IC50 values of 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively.
-
EMD 1204831
0 ImagesCat. No.: HY-164394CAS No.: 1100598-15-9EMD 1204831 is a potent and highly selective c-Met inhibitor which selectively suppresses the c-Met receptor tyrosine kinase activity with an IC50 of 9 nM. EMD 1204831 can be utilized in cancer research.
-
Entacapone acid
0 ImagesSynonyms: Tyrphostin AG1290Entacapone acid (Tyrphostin AG1290) is a tyrosine kinase inhibitor. Entacapone acid reduces hepatic protein synthesis rate (HPS) in vivo.
-
PF-04217903 phosphate
0 ImagesCat. No.: HY-12017CCAS No.: 1159490-83-1PF-04217903 phosphate is an orally active, highly selective ATP-competitive c-Met kinase inhibitor with a Ki value of 4.8 nM and a Kd value of 4.5 nM. PF-04217903 phosphate blocks c-Met and HGF signaling pathways, inhibits MET phosphorylation, and blocks downstream MAPK, PI3K/AKT and PLCγ1 pathways. PF-04217903 phosphate suppresses tumor proliferation, survival, migration, invasion, angiogenesis and metastasis, induces apoptosis, and enhances efferocytosis, Annexin A1 expression and resolution of inflammation. PF-04217903 phosphate retains activity against several c-Met mutants (M1131T, V1220I, H1094R). PF-04217903 phosphate increases the incidence of subarachnoid hemorrhage and reduces survival rate without altering aneurysm formation, and also prevents lymph node metastasis induced by VEGF inhibition. PF-04217903 phosphate is applicable to research related to tumors (pancreas, stomach, lung, brain, colon, breast, kidney, melanoma, etc.), intracranial aneurysms and inflammatory diseases (gouty arthritis, neutrophilic pleuritis).
-
Tyrosine kinase inhibitor (Standard)
0 ImagesCat. No.: HY-10421RCAS No.: 1021950-26-4Tyrosine kinase inhibitor (Standard) is the analytical standard of Tyrosine kinase inhibitor (HY-10421). This product is intended for research and analytical applications. Tyrosine kinase inhibitor is a potent tyrosine kinase inhibitor.
-
Juvenile hormone B 3 (mixture of diastereomers)
0 ImagesCat. No.: HY-W587689CAS No.: 120293-93-8Synonyms: Juvenile hormone III bisepoxide; Juvenile hormone bisepoxide; JHB3Juvenile hormone B 3 (Juvenile hormone III bisepoxide)(mixture of diastereomers) is a sesquiterpenoid hormone. Juvenile hormone B 3 can be isolated from corpus allatum (CA) of high dipterans like the fruitfly and Drosophila melanogaster. JHB3 has anti-metamorphic activity and induces Kr-h1 expression by directly interacting with juvenile hormone (JH) receptors (Met and Gce). Juvenile hormone B 3 can be used for insect lethality research.
-
Ningetinib Tosylate (Standard)
0 ImagesCat. No.: HY-107145RCAS No.: 1394820-77-9Ningetinib Tosylate (Standard) is the analytical standard of Ningetinib Tosylate (HY-107145). This product is intended for research and analytical applications. Ningetinib Tosylate is a potent, orally bioavailable small molecule tyrosine Kinase inhibitor (TKi) with IC50s of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and Axl, respectively.
-
T-1840383
0 ImagesCat. No.: HY-120661CAS No.: 1195779-24-8T-1840383 is a potent, ATP-competitive inhibitor of c-Met/VEGFR-2, with the IC50s of 1.9 nM, 7.7 nM, 2.2 nM and 5.5 nM for c-Met, VEGFR1, VEGFR2 and VEGFR3, respectively.
-
STA-1474 sodium
0 ImagesCat. No.: HY-13752BCAS No.: 1402907-09-8STA-1474 sodium is an orally active and highly selective HSP90 inhibitor, as well as a phosphate prodrug of the HSP90 inhibitor STA-9090 (HY-15205). STA-1474 sodium disrupts the chaperone function of HSP90 and promotes the degradation of client proteins. STA-1474 sodium inhibits the phosphorylation of Met, Akt and STAT3, thereby blocking related signaling pathways. STA-1474 sodium induces apoptosis and inhibits proliferation of osteosarcoma cells, and triggers the up-regulation of HSP70 and HSP90. STA-1474 sodium induces tumor regression and caspase-3 activation in mouse osteosarcoma xenograft models. STA-1474 sodium can be used in the research of osteosarcoma.
-
Crizotinib-d8
0 ImagesCat. No.: HY-50878S1CAS No.: 1523579-82-9Synonyms: PF-02341066-d8Crizotinib-d8 (PF-02341066-d8) is deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC50s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC50s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition.
-
CEP-40783 (Standard)
0 ImagesCat. No.: HY-100946RCAS No.: 1437321-24-8Synonyms: RXDX-106 (Standard)
-
Capmatinib dihydrochloride hydrate (Standard)
0 ImagesSynonyms: INC280 dihydrochloride hydrate (Standard); INCB-28060 dihydrochloride hydrate (Standard)Capmatinib (dihydrochloride hydrate) (Standard) is the analytical standard of Capmatinib (dihydrochloride hydrate). This product is intended for research and analytical applications. Capmatinib (INC280; INCB28060) dihydrochloride hydrate is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib dihydrochloride hydrate can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib dihydrochloride hydrate potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib dihydrochloride hydrate is largely metabolized by CYP3A4 and aldehyde oxidase.
-
(E/Z)-Afatinib (Standard)
0 ImagesSynonyms: (E/Z)-BIBW 2992 (Standard)(E/Z)-Afatinib (Standard) is the analytical standard of (E/Z)-Afatinib. This product is intended for research and analytical applications. (E/Z)-Afatinib ((E/Z)-BIBW 2992) is the mixture of (E)-Afatinib and (Z)-Afatinib. Afatinib (HY-10261) is an irreversible inhibitor of EGFR, by irreversibly binding to their ATP binding site to block activation of EGFR, HER2, HER4, and EGFRvIII. Afatinib used in co-administration with Temozolomide (HY-17364), potently targeting to EGFRvIII-cMet signaling in glioblastoma cells.
-
Ningetinib (Standard)
0 ImagesCat. No.: HY-107145ARCAS No.: 1394820-69-9Ningetinib (Standard) is the analytical standard of Ningetinib (HY-107145A). This product is intended for research and analytical applications. Ningetinib is a potent, orally bioavailable small molecule tyrosine Kinase inhibitor (TKi) with IC50s of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and Axl, respectively.
-
PHA-665752 (Standard)
0 ImagesCat. No.: HY-11107RCAS No.: 477575-56-7PHA-665752 (Standard) is the analytical standard of PHA-665752 (HY-11107). This product is intended for research and analytical applications. PHA-665752 is a selective, ATP-competitive, and active-site inhibitor of the catalytic activity of c-Met Kinase (Ki=4 nM; IC50=9 nM). PHA-665752 exhibits >50-fold selectivity for c-Met compared with a panel of diverse tyrosine and serine-threonine Kinases. PHA-665752 induces apoptosis and cell cycle arrest, and exhibits cytoreductive antitumor activity.
-
Capmatinib (Standard)
0 ImagesSynonyms: INC280 (Standard); INCB28060 (Standard)Capmatinib (Standard) is the analytical standard of Capmatinib. This product is intended for research and analytical applications. Capmatinib (INC280; INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib is largely metabolized by CYP3A4 and aldehyde oxidase.
-
NPS-1034 (Standard)
0 ImagesCat. No.: HY-100509RCAS No.: 1221713-92-3
-
Crizotinib (Standard)
0 ImagesSynonyms: PF-02341066 (Standard)Crizotinib (Standard) is the analytical standard of Crizotinib. This product is intended for research and analytical applications. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC50s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC50s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition.
-
LCRF-0004
0 ImagesCat. No.: HY-123225CAS No.: 1229611-73-7LCRF-0004 is a potent inhibitor of RON kinase, with the IC50 value of 10 nM. and a surprising result is also obtained regarding its c-Met inhibitory activity, with the IC50 value of 12 nM. LCRF-0004 plays an important role in cancer research.
